Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. WBD
4. AMC
5. FFAI
6. PAA
7. TLT
8. NVDA
9. NUAI
10. MSFT

Go back to Rocket Pharmaceuticals Announces Positive Gene Expression, Clinical Biomarker and Preliminary Functional Data from Phase 1 Trial of RP-A501 for the Treatment of Danon Disease
(NASDAQ: RCKT) Delayed: 3.32 -0.05 (1.48%)
Previous Close $3.37    52 Week High $ 
Open $3.40    52 Week Low $ 
Day High $3.41    P/E N/A 
Day Low $3.29    EPS $ 
Volume 209,509